

## Dr. Reddy's Laboratories announces launch of DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes

21 March 2026 | News

**Dr. Reddy's Obeda® semaglutide injection is available in 2 mg and 4 mg strengths**



Hyderabad-based Dr. Reddy's Laboratories has announced the launch of its injectable semaglutide under the brand name Obeda®, marking an important step in expanding access to advanced GLP-1 receptor agonist-based therapy for the management of type 2 diabetes in India.

Dr. Reddy's has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide.

In a head-to-head Phase III clinical study enrolling 312 participants, Dr. Reddy's Obeda® established non-inferior efficacy and a safety profile comparable to the innovator drug. It showed similar glycaemic reduction. Additionally, comparable results were observed for fasting glucose control, post-prandial glucose control, and therapeutic glycaemic response (achieving HbA1c <7.0%) at the end of the study. No anti-drug antibodies were detected, and the immunogenicity profile was similar to that of the innovator drug.

With both API development and manufacturing, as well as formulation development conducted entirely in-house, Obeda® reflects Dr. Reddy's strength in complex product development and peptide science. It also showcases the company's decade-long expertise in peptide technology and its commitment to bringing GLP-1 therapies to market to ensure access to

high-quality, affordable medicines and addressing India's evolving healthcare needs. As part of its future plans for GLP-1 therapies, the company will be looking at a fully integrated API and formulation approach, encompassing both development and manufacturing in-house.

Dr. Reddy's Obeda<sup>®</sup> injection is available in 2 mg and 4 mg strengths and comes in a pre-filled, disposable pen designed for subcutaneous, once-a-week administration, with robust cold-chain integrity maintained throughout distribution.

Each pen of both strengths will deliver a minimum of 4 weekly doses. The cost to the patient will be Rs 4,200 per month for both the strengths. Additionally, in a human-factors study involving 41 participants completing approximately 20 key tasks aligned with the USFDA's guidance for drug-device combination products, the Obeda<sup>®</sup> pen demonstrated non-inferior user-performance outcomes compared with the innovator pen.

As part of its patient support programme for Obeda<sup>®</sup>, Dr. Reddy's has developed SemaKare<sup>™</sup>, a comprehensive support system to enhance and streamline the patient journey. Supported by a digital app, SemaKare<sup>™</sup> offers onboarding guidance, field device-counsellor assistance, injection training, tele-support, therapy-adherence monitoring, and so on, to help improve treatment outcomes for patients.